Comparative Efficacy of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers after Coronary Artery Bypass Grafting
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Jeayoun | - |
dc.contributor.author | Park, Jungchan | - |
dc.contributor.author | Lee, Jong-Hwan | - |
dc.contributor.author | Min, Jeong Jin | - |
dc.contributor.author | Lee, Seung-Hwa | - |
dc.contributor.author | Lee, Young Tak | - |
dc.contributor.author | Kim, Wook Sung | - |
dc.contributor.author | Song, Sanghoon | - |
dc.contributor.author | Yeo, Jung Hyun | - |
dc.contributor.author | Cho, Hyojin | - |
dc.date.accessioned | 2021-09-10T07:24:30Z | - |
dc.date.available | 2021-09-10T07:24:30Z | - |
dc.date.issued | 2020-02-03 | - |
dc.identifier.issn | 2045-2322 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/19582 | - |
dc.description.abstract | Although angiotensin receptor blockers (ARBs) are considered as an alternative for those with angiotensin converting enzyme inhibitors (ACEi) intolerance, the comparative effectiveness of ARBs and ACEi remains controversial in patients who underwent coronary artery bypass grafting (CABG). We aimed to compare the clinical effects of the two types of renin-angiotensin-aldosterone system (RAAS) inhibitors in patients who underwent CABG. From January 2001 to January 2015, among the 5456 patients, data from 1198 (20.1%) patients who used a RAAS inhibitor at discharge were analyzed. These 1198 patients were classified into ACEi (N = 900) and ARB (N = 298) groups. The primary outcome was major adverse cardiovascular and cerebrovascular events (MACCE) during a median follow-up period of 48 months. Propensity-matched analysis revealed that the incidence of MACCE over a 48 month follow-up period did not differ between the groups (HR, 0.65; 95% CI, 0.36-1.21; p = 0.17), but it was significantly lower in the ARB group during the 12 month follow-up period (HR, 0.46; 95% CI, 0.22-0.96; p = 0.04). In conclusion, ARBs may have comparable protective effects to ACEi and be a reasonable alternative for intolerant patients after CABG. The beneficial effects of ARBs depending on follow-up period require further investigation. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Nature Publishing Group | - |
dc.title | Comparative Efficacy of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers after Coronary Artery Bypass Grafting | - |
dc.type | Article | - |
dc.publisher.location | 영국 | - |
dc.identifier.doi | 10.1038/s41598-020-58705-0 | - |
dc.identifier.scopusid | 2-s2.0-85078903156 | - |
dc.identifier.wosid | 000570138700001 | - |
dc.identifier.bibliographicCitation | Scientific Reports, v.10, no.1 | - |
dc.citation.title | Scientific Reports | - |
dc.citation.volume | 10 | - |
dc.citation.number | 1 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Science & Technology - Other Topics | - |
dc.relation.journalWebOfScienceCategory | Multidisciplinary Sciences | - |
dc.subject.keywordPlus | HIGH-RISK PATIENTS | - |
dc.subject.keywordPlus | MYOCARDIAL-INFARCTION | - |
dc.subject.keywordPlus | SECONDARY PREVENTION | - |
dc.subject.keywordPlus | HEART-FAILURE | - |
dc.subject.keywordPlus | MORTALITY | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | HYPERTENSION | - |
dc.subject.keywordPlus | TELMISARTAN | - |
dc.subject.keywordPlus | GUIDELINE | - |
dc.subject.keywordPlus | SYSTEM | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.